Abstract
This study was designed to investigate the effects of combination of ezetimibe, simvastatin and omega-3-fatty acids on lipoproteins in patients with mixed dyslipidemia. Among the 102 patients were screened 98 who met the inclusion and exclusion criteria after 6 weeks on a strict diet therapy were grouped into four treatment groups (2 patients left out in between). The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499 mg per 100 ml) and a total cholesterol level more than 200 mg per 100 ml. Present study was conducted on dyslipidemic patients receiving ezetimibe (10 mg) alone, simvastatin (20 mg) alone, omega-3-fatty acids (4 g) alone and combination of simvastatin (20 mg) and ezetimibe (10 mg) and omega-3-fattyacids (4g) daily for 12weeks. After 12 weeks treatment (Tc, LDL)was found decreased, Tg level reduced significantly and HDL level increased in the combination therapy (Simvastatin, ezetimibe and omega-3-fattyacids) than monotherapy. From the result it is concluded that combination therapy of these three may be considered as an optimal treatment option for patients with mixed dyslipidemia.
References
Goodman and Gilmans, The Pharmacological Basis Of Therapeutics. Ninth Edition. Mcgraw-Hill, USA.
Satoskhar RS., Rege N.N., Bhandarkar S.D., Pharmacology and pharmacotherapeutics, 22nd edition, 582-586.
Lin, Chen-Fang, Gau and Shiouh C., Impact of Ezetimibe Coadministered with Statins on Cardiovascular Events Following Acute Coronary Syndrome, Clinical Therapeutics, 33 (9), 12, 2011.
Lucia A and Karter A, synergistic effect of simvastatin and ezetimibe on lipid and pro- inflammatory profiles in pre- diabetic subjects, Diabetology & Metabolic Syndrome, 2, 34, 656, 2007.
Bays H, Drehobl M, Rosenblatt S, Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption, in 243 hypercholesterolemic subjects, Atherosclerosis, 151, 133, 2000.
Robinson J. G, Ballantyne C. M, Grundy S. M, and Polis A. B, Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome, American Journal of Cardiology, 103, 1694, 2000.
SanGiovanni J. P and Chew E.Y, The role of omega- 3 long-chain polyunsaturated fatty acids in health and disease of the retina, Progress in Retinal and Eye Research, 24, 87, 2005.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array